Kips Bay Liquidates As Its Bypass Graft Device Shows Poorly In Study
This article was originally published in The Gray Sheet
Executive Summary
The struggling Minnesota company made a last-ditch effort to complete the eMESH 1 trial of the eSVS Mesh device for coronary artery bypass graft surgery, but the firm, founded by device sector luminary Manny Villafana, has decided to give it up after the early results from the trial proved disappointing.
You may also be interested in...
Kips Bay Fires Staff, Cuts Costs To Keep eSVS Mesh In The Game
The company is downsizing to keep its clinical trial for its eSVS Mesh product on track. It estimates it currently has enough funds to last it through the year, but cautions it may take months to gather patient follow-up data.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign
Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.